Cargando…

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience

We present the preliminary toxicity data from the MRC COIN trial, a phase III randomised controlled trial of first-line therapy in advanced colorectal cancer, with particular reference to the addition of cetuximab to an oxaliplatin–fluoropyrimidine combination. A total of 804 patients were randomise...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adams, R A, Meade, A M, Madi, A, Fisher, D, Kay, E, Kenny, S, Kaplan, R S, Maughan, T S
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634710/ https://www.ncbi.nlm.nih.gov/pubmed/19165196 http://dx.doi.org/10.1038/sj.bjc.6604877

Ejemplares similares

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial
por: Madi, A, et al.
Publicado: (2012)

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
por: Adams, Richard A, et al.
Publicado: (2011)

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
por: Maughan, Timothy S, et al.
Publicado: (2011)

Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial
por: Wasan, Harpreet, et al.
Publicado: (2014)

Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study
por: Grenader, Tal, et al.
Publicado: (2016)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
por: Bang, Yeong Hak, et al.
Publicado: (2021)

Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms
por: Deng, Xunwei, et al.
Publicado: (2020)

Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients
por: Ruzzo, Annamaria, et al.
Publicado: (2014)

Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer
por: Punt, C.J.A., et al.
Publicado: (2023)

Revisiting oral fluoropyrimidine with cetuximab in metastatic colorectal cancer: Real-world data in Chinese population
por: Lam, Ka-On, et al.
Publicado: (2019)

Combination of oxaliplatin, fluorouracil, and leucovorin in the treatment of fluoropyrimidine-pretreated patients with metastatic colorectal cancer.
por: Lee, J. H., et al.
Publicado: (2001)

Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial
por: Garufi, C, et al.
Publicado: (2010)

Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study
por: Kullmann, F, et al.
Publicado: (2009)

Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options?
por: Knikman, Jonathan E., et al.
Publicado: (2020)

A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
por: Koo, Dong Hoe, et al.
Publicado: (2007)

Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer
por: Santoro, Valeria, et al.
Publicado: (2015)

A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?
por: Maughan, T S, et al.
Publicado: (2014)

MRC2020: improvements to Ximdisp and the MRC image-processing programs
por: Short, J. M., et al.
Publicado: (2023)

Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin
por: Narvi, Elli, et al.
Publicado: (2018)

Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?
por: Osumi, Hiroki, et al.
Publicado: (2015)

A narrative review of genetic factors affecting fluoropyrimidine toxicity
por: Gmeiner, William H.
Publicado: (2021)

Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer
por: SU, YUQI, et al.
Publicado: (2015)

Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy
por: Lee, Dae-Won, et al.
Publicado: (2019)

Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction
por: Baird, R, et al.
Publicado: (2011)

Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation
por: Balin-Gauthier, D, et al.
Publicado: (2008)

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
por: Lordick, F, et al.
Publicado: (2010)

Fluoropyrimidine-induced cardiotoxicity
por: Deac, Andrada Larisa, et al.
Publicado: (2020)

Polymorphism in miR-146a associated with clinical characteristics and outcomes in gastric cancer patients treated with adjuvant oxaliplatin and fluoropyrimidines
por: Liao, Yu-Qian, et al.
Publicado: (2015)

Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand‐foot syndrome
por: Watts, Katie, et al.
Publicado: (2022)

Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
por: Loganayagam, A, et al.
Publicado: (2013)

HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal Trial
por: Barber, Paul R, et al.
Publicado: (2019)

Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine): three case reports
por: Brickell, K, et al.
Publicado: (2003)

Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity
por: Meulendijks, Didier, et al.
Publicado: (2017)

Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients—Analysis of the Phase III AIO KRK-0207 Trial
por: Stintzing, Sebastian, et al.
Publicado: (2018)

Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer
por: Zhang, Zhan-Dong, et al.
Publicado: (2014)

MRC2014: Extensions to the MRC format header for electron cryo-microscopy and tomography
por: Cheng, Anchi, et al.
Publicado: (2015)

Toxicity of culture material of Fusarium verticillioides strain MRC 826 to nonhuman primates.
por: Gelderblom, W C, et al.
Publicado: (2001)

Oxaliplatin-Related Ocular Toxicity
por: Mesquida, Marina, et al.
Publicado: (2010)

Survival outcomes of adjuvant taxanes, platinum plus fluoropyrimidines versus platinum and fluoropyrimidines for gastric cancer patients after D2 gastrectomy: a retrospective propensity score-matched analysis
por: Wu, Lili, et al.
Publicado: (2021)

Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk
por: De Mattia, Elena, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9gritqq5p7kdtaj6gauo6jkip1